My Lords, from time to time I have been approached by plasma companies and vaccine companies about supply issues, particularly where there have been changes in the structure of the industry and a reduction in the number of producers of some of these products, and sometimes on the point of whether British companies may start to go out of business because of some of those structural changes. My question to the Minister is whether the amendment would actually help enable the Secretary of State to deal with some of those supply problems when this becomes an issue. It becomes an issue for those patients who really need that particular product when no other will do. Is this the kind of amendment that would help with these supply problem areas, which to my knowledge have been experienced from time to time, particularly in plasma and vaccine areas?
Health Service Medical Supplies (Costs) Bill
Proceeding contribution from
Lord Warner
(Crossbench)
in the House of Lords on Tuesday, 7 February 2017.
It occurred during Debate on bills on Health Service Medical Supplies (Costs) Bill.
About this proceeding contribution
Reference
778 c1655 Session
2016-17Chamber / Committee
House of Lords chamberSubjects
Librarians' tools
Timestamp
2017-02-10 18:30:32 +0000
URI
http://hansard.intranet.data.parliament.uk/Lords/2017-02-07/17020793000106
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Lords/2017-02-07/17020793000106
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Lords/2017-02-07/17020793000106